Clinuvel Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLVLY research report →
About the company
Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland. Their flagship therapeutic, SCENESSE, is a systemic photoprotective medication designed to shield adult patients suffering from erythropoietic protoporphyria (EPP) from light-induced damage. The company's development portfolio also features CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which stimulates extended cellular activity; and PRÉNUMBRA, an injectable liquid form of afamelanotide.
- CEO
- Philippe Jacques Wolgen
- IPO
- 2008
- Employees
- 100
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $370.52M
- P/E
- 15.77
- P/S
- 5.37
- P/B
- 2.06
- EV/EBITDA
- 11.55
- Div Yield
- 0.49%
- Gross Margin
- 63.71%
- Op Margin
- 39.39%
- Net Margin
- 33.79%
- ROE
- 13.29%
- ROIC
- 11.07%
- Revenue
- $95.02M · 7.76%
- Net Income
- $36.17M · 1.50%
- EPS
- $0.72 · 0.00%
- Op Income
- $45.73M
- FCF YoY
- 29.61%
- 52W High
- $9.00
- 52W Low
- $5.98
- 50D MA
- $6.78
- 200D MA
- $7.43
- Beta
- 0.61
- Avg Volume
- 2.08K
Get TickerSpark's AI analysis on CLVLY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CLVLY coverage
Recent articles, reports, and earnings notes.
No research on CLVLY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLVLY report →Similar companies
Peers in the same neighborhood.